About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ATG5 as a Serum Marker of Autophagy in Psoriatic Patient

NCT05279638·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Ayatallah Hamdi Abdelrahmim
CONTACT
01005482447 [email protected]

Lead

Sohag University

Age

18–55

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Psoriasis vulgaris of both sex, age 18-55 years

You may not be if

i. Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months

The record

StatusUnknown

PhaseNo phase

Taking part90

StartedFeb 2022

UpdatedMar 15, 2022

Conditions

Psoriasis Vulgaris Autophagy

Where1

Sohag University
Sohag, Egypt

Clareo Health | ATG5 as a Serum Marker of Autophagy in Psoriatic Patient